Inventiva to participate at the Jefferies Virtual Healthcare Conference
Daix (France), May 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need,
today announced that the Company will participate to the upcoming Jefferies Virtual Healthcare Conference,
being held virtually on June 1-4, 2021. During the event, members of the Company’s leadership will present a
corporate overview, participate in a fireside chat and engage in 1×1 investor meetings.